Lilly: Study shows Cymbalta 'signficantly' reduces back pain
INDIANAPOLIS A pain drug made by Eli Lilly & Co. “significantly” reduced chronic low back pain compared with placebo, according to a study announced Wednesday by Lilly.
The double-blind study, presented at the annual meeting of the American Academy of Pain Medicine in San Antonio, enrolled 401 patients over a 12-week period who took 60-mg of Cymbalta (duloxetine hydrochloride) once a day. Patients taking Cymbalta experienced a statistically significant reduction in back pain, measured by the Brief Pain Inventory, compared with the placebo group.
“Chronic low back pain affects a significant number of people,” lead study author and Lilly Research Laboratories neurologist Vladimir Skljarevski stated. “In fact, research suggests that the incidence of the condition may be as high as 48%.”
Forty-one patients – 30 from the study group and 11 from the placebo group – had to drop out of the study due to adverse side effects, which most commonly included nausea, headache, dry mouth, constipation and dizziness.